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Chondrogenic potential of human
articular chondrocytes and skeletal
stem cells: A comparative study
Siwei Li1, Bram G Sengers2, Richard OC Oreffo1 and Rahul S Tare1,2
Abstract
Regenerative medicine strategies have increasingly focused on skeletal stem cells (SSCs), in response to concerns such as
donor site morbidity, dedifferentiation and limited lifespan associated with the use of articular chondrocytes for cartilage
repair. The suitability of SSCs for cartilage regeneration, however, remains to be fully determined. This study has
examined the chondrogenic potential of human STRO-1-immunoselected SSCs (STRO-1þ SSCs), in comparison to
human articular chondrocytes (HACs), by utilising two bioengineering strategies, namely ‘‘scaffold-free’’ three-dimen-
sional (3-D) pellet culture and culture using commercially available, highly porous, 3-D scaffolds with interconnected
pore networks. STRO-1þ SSCs were isolated by magnetic-activated cell sorting from bone marrow samples of haema-
tologically normal osteoarthritic individuals following routine hip replacement procedures. Chondrocytes were isolated
by sequential enzymatic digestion of deep zone articular cartilage pieces dissected from femoral heads of the same
individuals. After expansion in monolayer cultures, the harvested cell populations were centrifuged to form high-density
3-D pellets and also seeded in the 3-D scaffold membranes, followed by culture in serum-free chondrogenic media under
static conditions for 21 and 28 days, respectively. Chondrogenic differentiation was determined by gene expression,
histological and immunohistochemical analyses. Robust cartilage formation and expression of hyaline cartilage-specific
markers were observed in both day-21 pellets and day-28 explants generated using HACs. In comparison, STRO-1þ SSCs
demonstrated significantly lower chondrogenic differentiation potential and a tendency for hypertrophic differentiation in
day-21 pellets. Culture of STRO-1þ SSCs in the 3-D scaffolds improved the expression of hyaline cartilage-specific
markers in day-28 explants, however, was unable to prevent hypertrophic differentiation of the SSC population. The
advantages of application of SSCs in tissue engineering are widely recognised; the results of this study, however, highlight
the need for further development of cell culture protocols that may otherwise limit the application of this stem cell
population in cartilage bioengineering strategies.
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Introduction
Regeneration of articular cartilage, damaged as a result
of trauma, injury or degeneration, remains a major
challenge in Orthopaedics. Currently, there are no
eﬀective pharmacological agents that promote compre-
hensive healing of articular cartilage defects. The devel-
opment of cell-based therapies to augment cartilage
repair has therefore received considerable interest in
recent years. Autologous chondrocyte implantation
(ACI) is a widely used clinical intervention for the func-
tional restoration of articular cartilage defects.1 For a
typical two-stage ACI procedure, articular chondro-
cytes are harvested from the cartilage biopsy taken
from the non weight-bearing region of the damaged
joint, expanded in 2-D monolayer cultures and re-
injected into the defect site under a periosteal ﬂap.1
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Although ACI has demonstrated promising clinical
results,2–4 there are a number of limitations associated
with the application of human articular chondrocytes
(HACs) in this technique, namely donor site morbidity,
limited source of cells, dediﬀerentiation of chondro-
cytes as a consequence of expansion in monolayer cul-
tures and their limited lifespan in vitro.5–7 Hence, there
is a pressing need for alternative eﬀective cell sources to
improve cartilage repair.
Skeletal stem cells (SSCs), synonymously referred to
as mesenchymal stem cells (MSCs) derived from post-
natal bone marrow stromal tissue, have attracted much
attention due to their extended self-renewal potential
and ability to diﬀerentiate into multiple stromal cell
lineages.8,9 Bone marrow MSCs can be induced to dif-
ferentiate into chondrocytes in vitro by utilisation of
3-D culture strategies in combination with chondroin-
ductive factors (e.g. TGF-b3) and growth supple-
ments.10 In comparison to autologous articular
chondrocytes, application of autologous bone
marrow-derived MSCs for articular cartilage repair is
associated with one less surgical procedure, therefore
reduced economic costs and minimal donor-site mor-
bidity, and good to comparable clinical outcomes for
cartilage repair.11–13 However, high variability in the
chondrogenic diﬀerentiation potential of SSCs from
diﬀerent individuals, coupled with reports of generation
of mechanically inferior ﬁbrocartilaginous repair tissue
by SSCs and tissue calciﬁcation, have limited the use of
this adult stem cell population for cartilage regener-
ation.14–16 It is therefore debatable whether SSCs pos-
sess all the desirable characteristics to surpass, and
hence replace articular chondrocytes in articular cartil-
age regeneration strategies.
Thus, SSCs and HACs obtained from the same
osteoarthritic individuals were compared in the present
study for their potential to generate hyaline cartilage-
like tissue, utilising two tissue engineering strategies,
namely ‘‘scaﬀold-free’’ pellet culture and culture in
highly porous 3-D Alvetex scaﬀolds.
Materials and methods
Chemicals and reagents were purchased from
Invitrogen (Paisley, UK) and Sigma-Aldrich
(Gillingham, UK) unless speciﬁed. Human bone
marrow and femoral head samples were obtained
from eight haematologically normal osteoarthritic indi-
viduals (three males and ﬁve females, mean age: 80 14
years) following routine total hip replacement surgery
at Southampton General Hospital. Only tissue that
would have been discarded was used in this study
with approval of the Southampton and South West
Hampshire Research Ethics Committee (Ref No. 194/
99/1 & 210/01).
Isolation of STRO-1-immunoselected SSCs
Following extraction of cells from bone marrow samples
in a-MEM, the cell suspension was gently layered over
Lymphoprep (Axis-Shield Diagnostic, Dundee, UK) and
centrifuged to remove red blood cells by sedimentation.
Bone marrow mononuclear cells (BMMNCs) collected
from the ‘buﬀy coat’ at the interphase were incubated
with the mouse monoclonal STRO-1 antibody (undi-
luted supernatant harvested from the STRO-1 hybri-
doma in-house), and the SSC-enriched STRO-1þ cell
population was isolated by MACS as described previ-
ously.17 STRO-1þ cells were cultured to conﬂuence in
monolayer cultures in basal medium (a-MEM supple-
mented with 10% (v/v) FCS, 100 unit/ml penicillin and
100mg/ml streptomycin); cultures were maintained in
humidiﬁed atmosphere at 37C, 5% CO2 and 21% O2.
Passage 2 cells were utilised for the experiments.
Isolation of HACs
HACs were isolated by sequential enzymatic digestion
of deep-zone articular cartilage pieces, dissected from
the non load-bearing region of the femoral heads.18 In
brief, cartilage pieces were sequentially digested with
500 mg/ml trypsin-EDTA for 30min, 1mg/ml hyaluro-
nidase for 15min and 10mg/ml collagenase B (ROCHE
Diagnostics, Burgess Hill, UK) on a rotating mixer
overnight at 37C. Isolated chondrocytes were cultured
to conﬂuence in monolayer cultures in a-MEM supple-
mented with 10% (v/v) FCS, 100 unit/ml penicillin,
100 mg/ml streptomycin and 100M ascorbate 2-phos-
phate. Cultures were maintained in humidiﬁed atmos-
phere at 37C, 5% CO2 and 21% O2. Passage 1 cells
were utilised for the experiments.
Pellet culture
Pellet cultures were performed in accordance with the
protocol published previously.19 HACs and STRO-1þ
SSCs were harvested at conﬂuence from monolayer cul-
tures and suspended in serum-free chondrogenic media
at ﬁnal concentrations of 0.6 105, 1 105, 2 105,
3 105 and 5 105 cells/ml. 1ml of cell suspension was
added to each sterile 25ml polycarbonate universal tube
and centrifuged at 400 g for 5minutes at 4C. The
resulting cell pellet was cultured in humidiﬁed atmos-
phere at 37C, 5% CO2 and 21% O2 for 21 days. The
serum-free chondrogenic medium was made up of a-
MEM supplemented with 10 ng/ml rhTGF-b3
(PeproTech, London, UK), 100M ascorbate-2-phos-
phate, 10 nM dexamethasone and 1X ITS liquid supple-
ment (10mg/ml insulin, 5.5 mg/ml transferrin and 5 ng/ml
selenite premix), and media changes were carried out
every two days over the 21-day culture period. For
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each cell type, 2–5 pellets were generated using each of
the above mentioned cell numbers. At the end of the
culture period, three pellets (generated using 3 105
HACs and STRO-1þ SSCs) were harvested for analysis
of chondrogenic gene expression, while two pellets from
each group were ﬁxed in 4% paraformaldehyde (PFA)
and used for histological examination.
Cell culture in Alvetex 3-D scaffold inserts
Commercially available Alvetex 3-D scaﬀold mem-
branes mounted in inserts suitable for 12-well plates
(Amsbio, Abingdon, UK; Cat. # AMS.AVP005-34)
were used in this study. The Alvetex scaﬀold inserts
were prepared according to manufacturer’s instruc-
tions. In brief, the scaﬀold inserts were initially
immersed in 70% ethanol for less than 1min and
then washed thoroughly with PBS, prior to incuba-
tion in plain a-MEM for 15minutes in a CO2 incu-
bator. The scaﬀold inserts were moved into 12-well
plates, and 1 106 cells suspended in 3.5ml chondro-
genic medium were gently added onto each scaﬀold
membrane and the plates were returned to humidiﬁed
atmosphere at 37C, 5% CO2 and 21% O2. 3–5 scaf-
fold inserts were seeded with each cell type per
patient. The inserts were not disturbed for the initial
three days to allow cell attachment and chondrogenic
media were changed thereafter every three days
during the 28-day culture period. At the end of the
culture period, three explants were harvested for ana-
lysis of chondrogenic gene expression, while two
explants from each group were ﬁxed in 4% parafor-
maldehyde (PFA) and used for histological
examination.
Analysis of gene expression
Three day-21 pellets/day-28 explants from each group
were pooled and lysed using 20-gauge needles for
extraction of total RNA using Qiagen RNeasy kit
(Qiagen, Manchester, UK) following manufacturer’s
instructions. The RNA samples were treated with
DNase-1 reagent and reverse-transcribed using the
SuperScript VILOTM kit (Invitrogen, Paisley, UK).
qPCR assays were carried out using the 7500 Real-
Time PCR system (Applied Biosystems, Paisley, UK)
for analysing the expression of chondrogenic genes,
namely Sox-9 (NM_000346 – F: 50 CCCTTCAACCT
CCCACACTA 30; R: 50 TGGTGGTCG GTGTA
GTCGTA 30), Col2a1 (NM_001844, NM_033150 – F:
50 CCTGGTCCCCCTGGTCTTGG 30; R: 50 CATC
AAATCCTCCAGCCATC 30), Aggrecan (NM_
001135, NM_013227 – F: 50GACGGCTTCCACCAG
TGT 30; R: 50 GTCTCCATAGCAGCCTTCC 30) and
Col10a1 (NM_000493 – F: 50 CCCACTACCCAAC
ACCAAGA 30; R: 50GTGGACCAGGAGTACC
TTGC 30). The expression of genes of interest was
normalised to the housekeeping gene/endogenous con-
trol, -actin (NM_ 001101 – F: 50 GGC
ATCCTCACCCTGAAGTA 30; R: 50 AGGTG
TGGTGCCAGATTTTC 30). Since the SYBR Green
method was used, primers were validated by
dissociation curve/melt curve analysis to rule out the
formation of primer dimers. The relative transcript
levels of genes of interest were analysed using the com-
parative CT method (CT method). For a valid
CT calculation, the eﬃciencies of target (gene of
interest) and reference (endogenous control) ampliﬁca-
tion were conﬁrmed to be equal. For each gene, the
group with the highest expression was assigned a
value of 1 and expression level in the other group was
determined as relative fold decrease. Fold relative tran-
script levels were expressed as mean SD for plotting
as bar graphs. Statistical analysis was performed at the
level of CT in order to exclude potential bias due to
averaging of data transformed through the 2CT
equation.
Histological analysis
PFA-ﬁxed samples were processed through graded
ethanol (50–100%) and histoclear (100%) prior to
embedding in paraﬃn wax. Sequential sections were
cut at 7 mm on the microtome and mounted on glass
slides for histological and immunohistochemical stain-
ing. Images were captured with Olympus dotSlide
virtual slide system (Olympus Microscopy, Southend-
on-Sea, UK).
Alcian blue and Sirius red (A/S) staining
Sections were stained with Alcian blue 8GX (5mg/ml in
1% (v/v) glacial acetic acid) and Sirius red F3B
(10mg/ml in saturated picric acid) following nuclear
staining with Weigert’s haematoxylin.20 Alcian blue
stained the proteoglycan-rich cartilage matrix, while
Sirius red stained the collagen-rich matrix.
Immunohistochemistry
After quenching endogenous peroxidase activity with
3% (v/v) H2O2 and blocking with 10mg/ml BSA in
PBS, sections were incubated with relevant primary
antiserum at 4C overnight. This was followed by
hour-long incubation each with the appropriate bioti-
nylated secondary antibody and ExtrAvidin-
Peroxidase. Visualisation of the immune complex
involved the avidin-biotin method linked to peroxidase
and AEC (3-amino-9-ethylcarbazole), resulting in a
reddish brown reaction product. Negative controls
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(omission of the primary antisera) were included in all
immunohistochemistry procedures. No staining was
observed in all negative control sections. All sections
were counter-stained with Alcian blue 8GX. The anti-
SOX-9 antibody (rabbit polyclonal, IgG, Millipore,
Watford, UK) was used at a dilution of 1:150 in
10mg/ml BSA in PBS, following the antigen retrieval
procedure, which involved heating sections in 0.01M
citrate buﬀer (pH 6.0) in a microwave for 5min
before the application of the standard immunohisto-
chemistry procedure. For immunostaining using anti-
collagen Type I, II and X antibodies, sections were
treated with Hyaluronidase (0.8mg/ml) at 37C for
20min in order to unmask the collagen ﬁbres and
render them accessible for immunostaining. The LF68
anti-collagen Type I antibody (rabbit IgG, gift from Dr
Larry Fisher), anti-collagen Type II antibody (rabbit
IgG, Calbiochem, Watford, UK) and anti-collagen
Type X antibody (rabbit IgG, Calbiochem, Watford,
UK) were used at dilutions of 1:1000, 1:500 and
1:100, respectively.
Statistical analysis
Results were presented as mean S.D. Statistical ana-
lysis was performed using Mann–Whitney U test.
Results were deemed signiﬁcant if the probability of
occurrence by random chance alone was less than 5%
(i.e. p< 0.05).
Results
Chondrogenic differentiation of HACs and STRO-1þ
SSCs in scaffold-free pellet culture
Day-21 pellets of HACs and STRO-1þ SSCs were har-
vested for analysis of chondrogenic gene expression,
and histological and immunohistochemical examin-
ation. Expression of chondrogenic genes in day-21 pel-
lets generated using 3 105 HACs and STRO-1þ SSCs
was measured by qPCR (Figure 1). Although expres-
sion of Sox-9, a key marker of chondrogenesis, was
detected in day-21 pellets of HACs and STRO-1þ
Figure 1. Analysis of expression of Sox-9, Aggrecan, Col2a1 and Col10a1 transcripts by real-time qPCR in day-21 pellets generated
using 3105 HACs and STRO-1þ SSCs. Expression levels of the chondrogenic genes were normalised to the expression of the
housekeeping gene, -Actin. For each gene, the group with the highest expression was assigned a value of 1 and the expression level in
the other group was determined as relative fold decrease. Results are expressed as mean SD; n¼ pellets from eight osteoarthritic
individuals; *p< 0.05 (values of CTwere used for statistical analysis).
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SSCs, levels of the Sox-9 transcript were signiﬁcantly
higher in HAC pellets compared to pellet cultures of
STRO-1þ SSCs. Expression levels of Col2a1, the gene
encoding collagen Type II – the hyaline cartilage-spe-
ciﬁc collagen, and Aggrecan, the gene encoding the
major proteoglycan in hyaline cartilage, were signiﬁ-
cantly lower in pellet cultures of STRO-1þ SSCs com-
pared to HACs. In contrast, expression of Col10a1, the
gene encoding collagen Type X – a marker of termin-
ally diﬀerentiated or hypertrophic chondrocytes, was
signiﬁcantly increased in pellet cultures of STRO-1þ
SSCs compared to day-21 pellets of HACs.
For analysis of cartilage formation and chondro-
genic diﬀerentiation, sections of day-21 pellets gener-
ated using 3 105 HACs (Figure 2) and STRO-1þ
SSCs (Figure 3) were stained with Alcian blue and
Sirius red (A/S), and immunostained with antibodies
against phenotypic chondrogenic proteins. HAC pellets
exhibited hyaline cartilage-like tissue, composed of
chondrocytes in distinct lacunae embedded in dense
proteoglycan matrix stained with Alcian blue. A layer
of Sirius red-stained ﬁbrous collagen was observed
prominently along the periphery of the pellets. SOX-9
was immunolocalised to majority of the chondrocytes
Figure 2. Histological and immunohistochemical examination of day-21 HAC pellet cultures. HACs from six osteoarthritic indi-
viduals (M85, F90, F86, F73, F92, F94) were cultured as 3-D pellets (3 105 cells per pellet) over a period of 21 days in chondrogenic
media. Sections stained with Alcian blue and Sirius red (A/S) demonstrated formation of hyaline cartilage-like tissue in all pellets.
Chondrogenic differentiation was confirmed by robust expression of SOX-9 in chondrocytes and collagen Type II in chondrocytes and
the surrounding extracellular matrix, coupled with negligible expression of collagen Type I and X. Scale bars for low and high
magnification images represent 200mm and 50 mm, respectively.
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of the pellets, and prominent presence of collagen Type
II was observed in the chondrocytes as well as the sur-
rounding extracellular matrix. Furthermore, the pellets
demonstrated negligible staining for collagen Type I, a
constituent of ﬁbrocartilage, and collagen Type X, a
phenotypic marker of hypertrophic cartilage.
In comparison to HAC pellets, day-21 pellets of
STRO-1þ SSCs demonstrated lack of hyaline carti-
lage-like tissue. Distinct regions of Sirius red-stained
matrix adjacent to small areas of Alcian blue-stained
cartilaginous tissue were observed in day-21 pellets of
some STRO-1þ SSCs (F86, F73, F92). Staining for
SOX-9 and collagen Type II in STRO-1þ SSC pellets
was not as extensive as in day-21 pellets of HACs and
complemented Sox-9 and Col2a1 gene expression.
Negligible staining for collagen Type I was accompa-
nied by expression of collagen Type X in a signiﬁcant
proportion of cells of the STRO-1þ SSC pellets that
mimicked Col10a1 gene expression. STRO-1þ SSCs
therefore exhibited hypertrophic diﬀerentiation and
were not able to generate robust hyaline cartilage-like
tissue in day-21 pellets.
To determine whether suboptimal chondrogenic dif-
ferentiation and cartilage formation were restricted to
pellets generated using 3 105 STRO-1þ SSCs, add-
itional pellets were generated using 0.6 105, 1 105,
Figure 3. Histological and immunohistochemical analysis of day-21 STRO-1þSSC pellet cultures. STRO-1-immunoselected SSCs
from the six osteoarthritic individuals (M85, F90, F86, F73, F92, F94) were cultured as 3-D pellets (3 105 cells per pellet) over a
period of 21 days in chondrogenic media. Sections stained with Alcian blue and Sirius red (A/S) demonstrated lack of hyaline cartilage-
like tissue in all pellets. Staining for SOX-9 and collagen Type II in STRO-1þ SSC pellets was not extensive. Negligible staining for
collagen Type I was accompanied by expression of collagen Type X in a large number of cells of the STRO-1þ SSC pellets. Scale bars for
low and high magnification images represent 200mm and 50 mm, respectively.
6 Journal of Biomaterials Applications 0(0)
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2 105 and 5 105 STRO-1þ SSCs from two osteo-
arthritic individuals (M85, M52). For comparison,
similar cell numbers were used to generate pellets of
HACs from the same individuals. Histological sections
of the day-21 pellets were stained with A/S and exam-
ined for cartilage formation (Figure 4). Formation of
robust hyaline cartilage-like tissue was observed con-
sistently in day-21 pellets generated using 0.6 105–
5 105 HACs, while day-21 pellets generated using
0.6 105–5 105 STRO-1þSSCs showed lack of hya-
line cartilage formation.
Generation of cartilaginous explants by HACs
and STRO-1þ SSCs cultured in Alvetex
3-D scaffolds
Following culture of HACs and STRO-1þ SSCs in
Alvetex 3-D scaﬀolds, expression levels of the key
chondrogenic genes, namely Sox-9, Aggrecan, Col2a1
and Col10a1, in day-28 explants were analysed by
qPCR (Figure 5). Robust expression of Sox-9,
Aggrecan and Col2a1 was observed in day-28 explants
of HACs. Interestingly, expression levels of Sox-9,
Aggrecan and Col2a1 in day-28 explants of STRO-1þ
SSCs were comparable to day-28 HAC explants.
Expression of the hypertrophic gene Col10a1 in day-
28 explants of STRO-1þ SSCs, however, remained sig-
niﬁcantly higher than day-28 HAC explants.
Day-28 explants of HACs (Figure 6) and STRO-1þ
SSCs (Figure 7) were characterised by the presence of
chondrocytes in lacunae embedded in Alcian blue-
stained proteoglycan matrix surrounded by a thin
layer of Sirius red-stained ﬁbrous collagen along the
periphery. The expression of SOX9 conﬁrmed robust
chondrogenic diﬀerentiation in explants of both cell
types. The collagenous matrix of day-28 explants of
HACs consisted of collagen Type II, while negligible
collagen Types I and X were observed. In addition to
robust staining for collagen Type II and negligible
expression of collagen Type I, staining for collagen
Type X was observed in some cells of day-28 SSC
explants.
Discussion
The present study has investigated the chondrogenic
potential of two distinct, but clinically relevant, cell
populations, namely HACs and SSCs, using
‘‘scaﬀold-free’’ pellet culture and culture in Alvetex
3-D scaﬀolds. To the best of our knowledge, this is
the ﬁrst study that has comprehensively analysed the
chondrogenic diﬀerentiation of HACs and SSCs in
Alvetex scaﬀolds following long-term in vitro culture.
Deep zone articular chondrocytes were utilised in this
work, since previous studies have reported that, in
osteoarthritis, degenerative changes are initiated in
the superﬁcial zone of articular cartilage and expression
of matrix metalloproteinases, including MMP-2,
MMP-3, MMP-11 and ADAMTS5, is signiﬁcantly
upregulated in superﬁcial zone chondrocytes.21–23 The
monoclonal antibody, STRO-1, capable of recognising
the trypsin-resistant, cell-surface antigen expressed by a
subset of bone marrow mononuclear cells enriched in
stem/progenitor cells, was used in the present study to
immunoselect the STRO-1þ SSC population from bone
marrow samples.24 The STRO-1 antibody is one of the
most widely used antibodies for selecting stem cell-
enriched populations from bone marrow, adipose
tissue, synovial tissue and dental pulp. The STRO-1þ
cell population of human bone marrow is enriched in
SSCs, which have the ability to transfer a functional
hematopoietic microenvironment in vitro and are able
to diﬀerentiate into multiple stromal cell types, includ-
ing smooth muscle cells, adipocytes, osteoblasts and
chondrocytes.25 Thus, by obtaining the two cell popu-
lations from each of the eight osteoarthritic individuals,
the study was able to make a reliable comparison
between the chondrogenic potential of the two distinct
cell types.
The 3-D pellet culture model has been widely
employed to stimulate chondrogenesis and generate
scaﬀold-free cartilaginous explants that are charac-
terised by morphological, gene and protein expression
proﬁles matching in vivo hyaline cartilage.10,19,26 In the
present study, while pellet culture served as an excellent
in vitro system to facilitate the generation of hyaline
cartilage-like tissue from monolayer-expanded, dedif-
ferentiated HACs, STRO-1þ SSCs from the same
eight osteoarthritic individuals exhibited hypertrophic
diﬀerentiation and lacked the ability to generate hyaline
cartilage in day-21 pellets. In a separate study, which
examined the chondrogenic potential of articular chon-
drocytes and the heterogeneous bone marrow stromal
cell (BMSC) population obtained from 30 osteoarth-
ritic subjects, chondrocytes were shown to exhibit
robust chondrogenic potential in micromass cultures
compared to bone marrow stromal cells (BMSCs),
which, unlike articular chondrocytes, expressed signiﬁ-
cantly higher levels of Col1a1 and Col10a1 in the micro-
mass cultures.27 Likewise, lack of hypertrophy and
terminal diﬀerentiation were observed in pellet cultures
of monolayer-expanded HACs, in contrast to pellets of
BMSCs, which demonstrated hypertrophy, extensive
calciﬁcation and vascular invasion upon subcutaneous
implantation in immunocompromised mice.28
Moreover, aggregates of the relatively homogeneous
STRO-1-immunoselected SSC population cultured for
3 weeks in the presence of 10 ng/ml TGF-b1/3 were
characterised by the robust expression of Col10a1/
Type X collagen.25,29
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Figure 4. Examination of chondrogenic differentiation in day-21 pellets generated using 0.6 105, 1 105, 2 105 and 5 105
HACs and STRO-1þ SSCs from two osteoarthritic individuals (M85, M52). Histological sections of the day-21 pellets were stained
with Alcian blue and Sirius red (A/S). Formation of hyaline cartilage-like tissue was observed consistently in day-21 pellets generated
using 0.6 105–5 105 HACs, while day-21 pellets generated using 0.6 105–5 105 STRO-1þ SSCs demonstrated lack of hyaline
cartilage formation. Scale bars for low and high magnification images represent 200 mm and 50mm, respectively.
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Thus, results of the work presented here and in the
aforementioned studies have demonstrated that STRO-
1þ SSCs and BMSCs lack the ability to generate robust
hyaline cartilage-like tissue in high density, scaﬀold-
free, 3-D culture techniques, such as pellet, aggregate
or micromass culture. This is because STRO-1þ cells
have a lower chondrogenic diﬀerentiation potential
compared to articular chondrocytes in the pellet culture
system and a predisposition for hypertrophic diﬀeren-
tiation even in the presence of TGF-b1/3. Although the
STRO-1þ cell population is enriched in SSCs, which are
able to diﬀerentiate into multiple stromal cell lineages,
including the chondrogenic lineage, application of the
STRO-1 antibody alone does not yield a homogenous
population comprising solely of multipotent SSCs. This
is because the STRO-1 antibody also selects other cell
types from the bone marrow, including the osteopro-
genitor subpopulation.30 It is therefore possible that the
contaminating cell types within the heterogeneous
STRO-1þ cell population, especially the osteoprogeni-
tor cells, which are committed to diﬀerentiate into the
osteogenic lineage, aﬀect the chondrogenic diﬀerenti-
ation of the SSC subpopulation of the STRO-1þ cell
population. Moreover, it has been suggested that a
hypertrophic chondrocyte phenotype typical of the
transient cartilage observed in the process of endochon-
dral ossiﬁcation is the default lineage intrinsic to bone
marrow-derived SSCs.31
Although articular chondrocytes undergo dediﬀer-
entiation during monolayer culture, this is a transient
phenotype, as the cells are believed to retain their
‘‘developmental memory’’, most likely mediated by epi-
genetic mechanisms such as DNA methylation, which
assists in preventing hypertrophic diﬀerentiation,
calciﬁcation and vascular invasion.28 Articular chon-
drocytes therefore retain their chondrogenic diﬀerenti-
ation potential and produce hyaline cartilage-like tissue
in the 3-D environment of the pellet culture system.
In comparison to pellet culture, the present study
demonstrated a signiﬁcant improvement in the expres-
sion of hyaline cartilage-speciﬁc markers by STRO-
1þSSCs following culture in the Alvetex 3-D scaﬀold
membranes. In vivo, articular chondrocytes receive
oxygen and nutrients mainly via diﬀusion from the
capillaries of the synovium into the synovial ﬂuid and
then into the cartilage matrix.32 In vitro, mass transport
Figure 5. Analysis of expression of Sox-9, Aggrecan, Col2a1 and Col10a1 transcripts by real-time qPCR in day-28 explants of HACs
and STRO-1þ SSCs cultured in Alvetex 3-D scaffolds. Expression levels of the chondrogenic genes were normalised to the
expression of the housekeeping gene, -Actin. For each gene, the group with the highest expression was assigned a value of 1 and the
expression level in the other group was determined as relative fold decrease. Results are expressed as mean SD; n¼ explants from
eight osteoarthritic individuals; *p< 0.05 (values of CTwere used for statistical analysis).
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limitations and oxygen diﬀusion gradients in the
macroscopic pellets have been shown to be signiﬁcant
obstacles to robust chondrogenesis of bone marrow-
derived MSCs.33 In contrast, highly porous scaﬀolds
with interconnected pore networks promote cartilage
formation due to improved inﬁltration of cells,
enhanced mass transportation of oxygen and nutrients,
and eﬃcient clearance of metabolic wastes.34,35 Thus,
porosity, pore size and interconnectivity are important
architectural properties of a scaﬀold that inﬂuence pro-
duction of cartilage matrix.36
The highly porous (around 90% porosity) Alvetex
3-D scaﬀolds are made from inert polystyrene (a sub-
strate widely used in cell culture) and are characterised
by the presence of interconnected pore networks. It is
likely that the relatively thin membrane-like structure
(200mm thickness), coupled with the highly intercon-
nected and accessible pores of the Alvetex scaﬀold
contributed to the optimal diﬀusion of gases, nutrients
and waste metabolites between the cells and culture
medium during the prolonged culture period, and facili-
tated chondrogenic diﬀerentiation of the skeletal cell
populations. Stiﬀness of the scaﬀold can inﬂuence the
mechanical environment in which cells are cultured,
and it is predicted that increasing the stiﬀness of the
scaﬀold enhances cartilage formation and reduces the
amount of ﬁbrous tissue formation in the osteochon-
dral defect.37 Since stiﬀness of the Alvetex 3-D
Figure 6. Histological and immunohistochemical analysis of day-28 HAC explants. HACs from six osteoarthritic individuals (M85,
F90, F86, F73, F92, F94) were cultured in Alvetex 3-D scaffolds for 28 days in chondrogenic media. Sections of the cartilaginous
explants demonstrated presence of chondrocytes in lacunae embedded in Alcian blue-stained proteoglycan matrix surrounded by a
thin layer of Sirius red-stained fibrous collagen along the periphery. Chondrogenic differentiation was confirmed by robust staining for
SOX-9 and collagen Type II, and negligible staining for collagens Type I and Type X. Scale bars for low and high magnification images
represent 200mm and 50 mm, respectively.
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scaﬀold has not been assessed in the current study, it is
not possible to comment on the eﬀect of scaﬀold stiﬀ-
ness and the inﬂuence of the mechanical environment
on chondrogenic diﬀerentiation of the skeletal cells.
It is important to note that although expression of
chondrogenic markers is signiﬁcantly improved as a
result of culture of STRO-1þ SSCs in the scaﬀolds,
hypertrophic diﬀerentiation is not prevented. The results
therefore suggest that bone marrow-derived STRO-1þ
SSCs may indeed diﬀer from articular chondrocytes
with respect to their ultimate cellular fate, i.e. STRO-1þ
SSCs adopt a transient rather than stable articular chon-
drocyte phenotype and undergo terminal diﬀerentiation.
In order to maximise the potential of this adult stem cell
population for cartilage repair, culture of SSCs in 3-D
scaﬀolds with interconnected highly porous architecture
should be complemented by improvements/modiﬁcations
to existing protocols of in vitro chondrogenesis, speciﬁc-
ally to prevent the phenotypic drift towards hypertrophic
diﬀerentiation. This can include strategies such as locking
SSCs in the desired diﬀerentiation state, for example, by
establishment of DNA methylation patterns to silence
the expression of hypertrophic genes, or co-culture of
HACs and SSCs in 3-D chondroinductive low oxygen
tension environments to reduce the incidence of hyper-
trophy by promoting cross-talk between the two skeletal
cell populations, or application of mechanical loading to
improve cartilage formation and limit hypertrophy.
Figure 7. Histological and immunohistochemical examination of day-28 STRO-1þ SSC explants. STRO-1-immunoselected SSCs
from six osteoarthritic individuals (M85, F90, F86, F73, F92, F94) were cultured in Alvetex 3-D scaffolds for 28 days in chondrogenic
media. The overall histology of the cartilaginous explants stained with Alcian blue and Sirius red (A/S) was comparable to that of HAC
explants. Chondrogenic differentiation of STRO-1þ SSCs was significantly improved as demonstrated by the robust expression of
SOX-9 and collagen Type II, and negligible staining for collagen Type I. Staining for collagen Type X was observed in some cells of the
day-28 explants . Scale bars for low and high magnification images represent 200 mm and 50mm, respectively.
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In addition to the multipotent SSC subpopulation,
the STRO-1þ population of human bone marrow con-
tains osteoprogenitor cells, a signiﬁcant proportion of
glycophorin A-expressing nucleated erythroid cells and
a small subset of B-lymphocytes.24,30,38 It is therefore
not possible to obtain a homogenous population com-
prising solely of SSCs by using the STRO-1 antibody
alone. A cell sorting approach based on positive selec-
tion for the antigen recognised by STRO-1 and nega-
tive selection for glycophorin A would be an eﬀective
initial strategy to minimise the heterogeneity of the
STRO-1þ cell population and optimise the cellular
starting material for tissue engineering. Additionally,
a number of studies have shown that CD271þ,
CD146þ, CD105þ and CD29þ mesenchymal stem
cells (MSCs) exhibit higher chondrogenic potential in
comparison to other MSC subpopulations, suggesting
that these cell-surface antigens can be eﬀectively used
to isolate MSC subpopulations characterised by
robust chondrogenic potential.39–42 Thus, an improved
SSC enrichment strategy in the form of positive selec-
tion for the antigen recognised by STRO-1 and
CD271/ CD146/ CD105/CD29, in combination with
negative selection for glycophorin-A, would facilitate
isolation of relatively homogenous subpopulations of
SSCs (e.g. STRO-1þCD271þglycophorin A SSCs)
from the heterogeneous STRO-1þ population that
have enhanced chondrogenic potential and are suit-
able for bioengineering cartilage.
Conclusion
The present study has demonstrated that monolayer-
expanded HACs possess excellent chondrogenic poten-
tial in both ‘‘scaﬀold-free’’ pellet culture and culture
using 3-D scaﬀolds. In contrast, STRO-1þ SSCs exhibit
signiﬁcantly lower chondrogenic diﬀerentiation poten-
tial in ‘‘scaﬀold-free’’ pellet culture. Although the appli-
cation of highly porous 3-D scaﬀolds with
interconnected pore network can improve the expres-
sion of chondrogenic markers by STRO-1þ SSCs, this
is unable to prevent the phenotypic drift of the SSC
population towards hypertrophy. Development of
appropriate strategies to prevent hypertrophic diﬀeren-
tiation is therefore a crucial step in delivering improved
chondrogenic cell therapies from adult SSCs.
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